Relevant bibliographies by topics / Nanomedicine – Research

Academic literature on the topic 'Nanomedicine – Research'

Author: Grafiati
Published: 10 December 2022
Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nanomedicine – Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nanomedicine – Research"

1

Qiao, Huiting, Libin Wang, Jintao Han, Yingmao Chen, Daifa Wang, and Deyu Li. "The Mutual Beneficial Effect between Medical Imaging and Nanomedicine." Journal of Nanomaterials 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/764095.

Full text
Abstract:
The reports on medical imaging and nanomedicine are getting more and more prevalent. Many nanoparticles entering into the body act as contrast agents, or probes in medical imaging, which are parts of nanomedicines. The application extent and the quality of imaging have been improved by nanotechnique. On one hand, nanomedicines advance the sensitivity and specificity of molecular imaging. On the other hand, the biodistribution of nanomedicine can also be studiedin vivoby medical imaging, which is necessary in the toxicological research. The toxicity of nanomedicine is a concern which may slow down the application of nanomedical. The quantitative description of the kinetic process is significant. Based on metabolic study on radioactivity tracer, a scheme of pharmacokinetic research of nanomedicine is proposed. In this review, we will discuss the potential advantage of medical imaging in toxicology of nanomedicine, as well as the advancement of medical imaging prompted by nanomedicine.
APA, Harvard, Vancouver, ISO, and other styles
2

Munir, Muhammad Usman. "Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue." Cancers 14, no. 12 (June 13, 2022): 2904. http://dx.doi.org/10.3390/cancers14122904.

Full text
Abstract:
Nanomedicine has been under investigation for several years to improve the efficiency of chemotherapeutics, having minimal pharmacological effects clinically. Ineffective tumor penetration is mediated by tumor environments, including limited vascular system, rising cancer cells, higher interstitial pressure, and extra-cellular matrix, among other things. Thus far, numerous methods to increase nanomedicine access to tumors have been described, including the manipulation of tumor micro-environments and the improvement of nanomedicine characteristics; however, such outdated approaches still have shortcomings. Multi-functional convertible nanocarriers have recently been developed as an innovative nanomedicine generation with excellent tumor infiltration abilities, such as tumor-penetrating peptide-mediated transcellular transport. The developments and limitations of nanomedicines, as well as expectations for better outcomes of tumor penetration, are discussed in this review.
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Ruibing, Paul S. Billone, and Wayne M. Mullett. "Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials." Journal of Nanomaterials 2013 (2013): 1–12. http://dx.doi.org/10.1155/2013/629681.

Full text
Abstract:
Nanomedicine, defined as the application of nanotechnology in the medical field, has the potential to significantly change the course of diagnostics and treatment of life-threatening diseases, such as cancer. In comparison with traditional cancer diagnostics and therapy, cancer nanomedicine provides sensitive cancer detection and/or enhances treatment efficacy with significantly minimized adverse effects associated with standard therapeutics. Cancer nanomedicine has been increasingly applied in areas including nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents in laboratory and animal model research. In recent years, the successful introduction of several novel nanomedicine products into clinical trials and even onto the commercial market has shown successful outcomes of fundamental research into clinics. This paper is intended to examine several nanomedicines for cancer therapeutics and/or diagnostics-related applications, to analyze the trend of nanomedicine development, future opportunities, and challenges of this fast-growing area.
APA, Harvard, Vancouver, ISO, and other styles
4

Susa, Francesca, Tania Limongi, Bianca Dumontel, Veronica Vighetto, and Valentina Cauda. "Engineered Extracellular Vesicles as a Reliable Tool in Cancer Nanomedicine." Cancers 11, no. 12 (December 9, 2019): 1979. http://dx.doi.org/10.3390/cancers11121979.

Full text
Abstract:
Fast diagnosis and more efficient therapies for cancer surely represent one of the huge tasks for the worldwide researchers’ and clinicians’ community. In the last two decades, our understanding of the biology and molecular pathology of cancer mechanisms, coupled with the continuous development of the material science and technological compounds, have successfully improved nanomedicine applications in oncology. This review argues on nanomedicine application of engineered extracellular vesicles (EVs) in oncology. All the most innovative processes of EVs engineering are discussed together with the related degree of applicability for each one of them in cancer nanomedicines.
APA, Harvard, Vancouver, ISO, and other styles
5

Bai, Xue, Zara L. Smith, Yuheng Wang, Sam Butterworth, and Annalisa Tirella. "Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review." Micromachines 13, no. 10 (September 28, 2022): 1623. http://dx.doi.org/10.3390/mi13101623.

Full text
Abstract:
Although nanomedicine has been highly investigated for cancer treatment over the past decades, only a few nanomedicines are currently approved and in the market; making this field poorly represented in clinical applications. Key research gaps that require optimization to successfully translate the use of nanomedicines have been identified, but not addressed; among these, the lack of control of the release pattern of therapeutics is the most important. To solve these issues with currently used nanomedicines (e.g., burst release, systemic release), different strategies for the design and manufacturing of nanomedicines allowing for better control over the therapeutic release, are currently being investigated. The inclusion of stimuli-responsive properties and prolonged drug release have been identified as effective approaches to include in nanomedicine, and are discussed in this paper. Recently, smart sustained release nanoparticles have been successfully designed to safely and efficiently deliver therapeutics with different kinetic profiles, making them promising for many drug delivery applications and in specific for cancer treatment. In this review, the state-of-the-art of smart sustained release nanoparticles is discussed, focusing on the design strategies and performances of polymeric nanotechnologies. A complete list of nanomedicines currently tested in clinical trials and approved nanomedicines for cancer treatment is presented, critically discussing advantages and limitations with respect to the newly developed nanotechnologies and manufacturing methods. By the presented discussion and the highlight of nanomedicine design criteria and current limitations, this review paper could be of high interest to identify key features for the design of release-controlled nanomedicine for cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

Tanaka, Hiroyoshi, Takuya Nakazawa, Atsushi Enomoto, Atsushi Masamune, and Mitsunobu Kano. "Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment." Cancers 15, no. 3 (January 24, 2023): 724. http://dx.doi.org/10.3390/cancers15030724.

Full text
Abstract:
Pancreatic cancer is notorious for its dismal prognosis. The enhanced permeability and retention (EPR) effect theory posits that nanomedicines (therapeutics in the size range of approximately 10–200 nm) selectively accumulate in tumors. Nanomedicine has thus been suggested to be the “magic bullet”—both effective and safe—to treat pancreatic cancer. However, the densely fibrotic tumor microenvironment of pancreatic cancer impedes nanomedicine delivery. The EPR effect is thus insufficient to achieve a significant therapeutic effect. Intratumoral fibrosis is chiefly driven by aberrantly activated fibroblasts and the extracellular matrix (ECM) components secreted. Fibroblast and ECM abnormalities offer various potential targets for therapeutic intervention. In this review, we detail the diverse strategies being tested to overcome the fibrotic barriers to nanomedicine in pancreatic cancer. Strategies that target the fibrotic tissue/process are discussed first, which are followed by strategies to optimize nanomedicine design. We provide an overview of how a deeper understanding, increasingly at single-cell resolution, of fibroblast biology is revealing the complex role of the fibrotic stroma in pancreatic cancer pathogenesis and consider the therapeutic implications. Finally, we discuss critical gaps in our understanding and how we might better formulate strategies to successfully overcome the fibrotic barriers in pancreatic cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

Foldvari, Marianna. "Nanomedicine research in Canada." Nanomedicine: Nanotechnology, Biology and Medicine 2, no. 4 (December 2006): 296. http://dx.doi.org/10.1016/j.nano.2006.10.088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Xiaojun. "Nanomedicine Research in China." Nanomedicine: Nanotechnology, Biology and Medicine 2, no. 4 (December 2006): 297. http://dx.doi.org/10.1016/j.nano.2006.10.090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hunziker, Patrick. "Nanomedicine Research in Switzerland." Nanomedicine: Nanotechnology, Biology and Medicine 2, no. 4 (December 2006): 299. http://dx.doi.org/10.1016/j.nano.2006.10.097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Eaton, Mike. "Nanomedicine: Industry-wise research." Nature Materials 6, no. 4 (April 2007): 251–53. http://dx.doi.org/10.1038/nmat1879.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nanomedicine – Research"

1

McDonagh, Philip R. III. "Radioprotective Cerium Oxide Nanoparticles: Molecular Imaging Investigations of CONPs’ Pharmacokinetics, Efficacy, and Mechanisms of Action." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4314.

Full text
Abstract:
Cerium oxide nanoparticles (CONPs) are being investigated for several anti-oxidant applications in medicine. One of their most promising applications is as a radioprotective drug, an area of research in need due to the severe side effects from radiation therapy. In this work, the potential of CONPs as a radioprotective drug is examined using four criteria: favorable biodistribution/pharmacokinetics, low toxicity, ability to protect normal tissue from radiation damage, and lack of protection of tumor. The mechanisms of action of CONPs are also studied. Biodistribution was determined in radiolabeled CONPs with surface coatings including citrate, dextran T10-amine (DT10-NH2), dextran T10-polyethylene glycol (DT10-PEG), dextran T10-sulfobetaine (DT10-SB) and poly(acrylic acid) (PAA), and compared to uncoated. 89Zr was incorporated into CONPs for positron emission tomography (PET) imaging and ex vivo tissue analysis in tumor bearing mice. Compared to uncoated [89Zr]CONPs, coated [89Zr]CONPs showed improved biodistribution, including significantly enhanced renal clearance of PAA- [89Zr]CONPs. The toxicity of CONPs was evaluated in vitro and in vivo, with low toxicity at therapeutic doses. After clinically mimetic radiation therapy, pre-treatment of mice with coated and uncoated CONPs showed greater than 50% reduction of cell death in normal colon tissue, comparable to the clinically available radioprotective drug amifostine. Tumor control after irradiation of spontaneous colon tumors was unchanged with PAA-CONP pre-treatment, while citrate, DT10-PEG, and uncoated CONP pre-treatment had slightly less tumor control. Xenograft tumors were irradiated after pH normalizing treatment with sodium bicarbonate and PAA-CONP pre-treatment. Treatment of these tumors showed slightly less tumor control than irradiation alone or PAA-CONP plus irradiation, demonstrating that the acidic pH of the tumor microenvironment may be the basis of preventing CONPs’ radioprotective properties in tumor. These studies show that, among the variations of CONPs tested, PAA-CONP shows the most promise for its good biodistribution and quick clearance, low toxicity, ability to protect normal tissue, and lack of protection of tumor, meeting all the criteria set forth for an ideal radioprotective drug. Further studies on the effects of pH on CONPs actions may further elucidate their mechanisms of action, advancing them as a candidate for use as a radioprotective drug during radiation therapy.
APA, Harvard, Vancouver, ISO, and other styles
2

Geng, Jia. "Membrane embedded channel of bacteriophage phi29 DNA packaging motor for single molecule sensing and nanomedicine." University of Cincinnati / OhioLINK, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1336507840.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shu, Yi. "Assembly of Phi29 pRNA Nanoparticles for Gene or Drug Delivery and for Application in Nanotechnology and Nanomedicine." University of Cincinnati / OhioLINK, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1336683831.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Adjei, Isaac Morris. "Nanoparticle-mediated cancer therapy for primary and metastasized tumors." Case Western Reserve University School of Graduate Studies / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=case1386342707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Krishnan, Vinu. "Design and Synthesis of Nanoparticle “PAINT-BRUSH” Like Multi-Hydroxyl Capped Poly(Ethylene Glycol) Conjugates for Cancer Nanotherapy." Akron, OH : University of Akron, 2008. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=akron1217677351.

Full text
Abstract:
Thesis (M.S.)--University of Akron, Dept. of Biomedical Engineering, 2008.
"August, 2008." Title from electronic thesis title page (viewed 12/9/2009) Advisor, Stephanie T. Lopina; Committee members, Amy Milsted, Daniel B. Sheffer, Daniel Ely; Department Chair, Daniel B. Sheffer; Dean of the College, George K. Haritos; Dean of the Graduate School, George R. Newkome. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
6

Seshadri, Dhruv Ramakrishna. "Immuno-nanotherapeutics to Inhibit Macrophage Polarization for Non-Small-Cell Lung Cancers." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case151084330337552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Franke, Christina E. "Tobacco Mosaic Virus Nanocarrier for Restored Cisplatin Efficacy in Platinum-Resistant Ovarian Cancer." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1493810190306879.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shoffstall, Andrew J. "The Use of Synthetic Platelets to Augment Hemostasis." Case Western Reserve University School of Graduate Studies / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=case1363775111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ferreira, Rodrigo Alberto de Jesus. "Few-cycle laser for realtime nanomedicine research." Master's thesis, 2018. https://hdl.handle.net/10216/121643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ferreira, Rodrigo Alberto de Jesus. "Few-cycle laser for realtime nanomedicine research." Dissertação, 2018. https://hdl.handle.net/10216/121643.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Nanomedicine – Research"

1

Handbook of harnessing biomaterials in nanomedicine: Preparation, toxicity, and applications. Singapore: Pan Stanford Pub., 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Institute of Medicine (U.S.). Planning Committee on Policy Issues in Nanotechnology and Oncology and National Cancer Policy Forum (U.S.), eds. Nanotechnology and oncology: Workshop summary. Washington,D.C: National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fymat, Alain L. Nanomedicine: My Collected Research Works in Nanomedicine Research. Tellwell Talent, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fymat, Alain L. Nanomedicine: My Collected Research Works in Nanomedicine Research. Tellwell Talent, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Louvel, Séverine. Policies and Politics of Interdisciplinary Research: Nanomedicine in France and in the United States. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Louvel, Séverine. Policies and Politics of Interdisciplinary Research: Nanomedicine in France and in the United States. Taylor & Francis Group, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Policies and Politics of Interdisciplinary Research: Nanomedicine in France and in the United States. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Louvel, Séverine. Policies and Politics of Interdisciplinary Research: Nanomedicine in France and in the United States. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Patlak, Margie, Institute of Medicine, Board on Health Care Services, National Cancer Policy Forum, and Christine Micheel. Nanotechnology and Oncology: Workshop Summary. National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patlak, Margie, Institute of Medicine, Board on Health Care Services, National Cancer Policy Forum, and Christine Micheel. Nanotechnology and Oncology: Workshop Summary. National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Nanomedicine – Research"

1

Louvel, Séverine. "Defining nanomedicine." In The Policies and Politics of Interdisciplinary Research, 28–51. Milton Park, Abingdon, Oxon ; New York, NY : Routledge, 2021. |: Routledge, 2020. http://dx.doi.org/10.4324/9780429201295-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jain, Kewal K. "Research and Future of Nanomedicine." In The Handbook of Nanomedicine, 493–503. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-983-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jain, Kewal K. "Research and Future of Nanomedicine." In The Handbook of Nanomedicine, 621–36. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6966-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jain, Kewal K. "Nanotechnologies for Basic Research Relevant to Medicine." In The Handbook of Nanomedicine, 59–111. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-983-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jain, Kewal K. "Nanotechnologies for Basic Research Relevant to Medicine." In The Handbook of Nanomedicine, 73–132. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6966-1_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sharma, Ajay, Anil Kumar, Hardeep Singh Tuli, Rajshree Khare, and Anil K. Sharma. "Flavan-3-Ols Research: From Chemistry to Nanomedicine." In Nanotechnology Horizons in Food Process Engineering, 39–75. New York: Apple Academic Press, 2023. http://dx.doi.org/10.1201/9781003305385-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rajesh Kumar, T., S. Anitha, P. Sangavi, R. Srinithi, K. Langeswaran, and R. Sangeetha. "Applications of Nanomedicine in Animal Models of Cancer." In Handbook of Animal Models and its Uses in Cancer Research, 1–14. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-1282-5_59-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Drobne, Damjana, Sara Novak, Andreja Erman, and Goran Dražić. "New Opportunities for FIB/SEM EDX in Nanomedicine: Cancerogenesis Research." In Biological Field Emission Scanning Electron Microscopy, 533–43. Chichester, UK: John Wiley & Sons, Ltd, 2019. http://dx.doi.org/10.1002/9781118663233.ch25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ray Banerjee, Ena. "Nanomedicine: Nanoparticles and Its Relevance in Drug Discovery vis-a-vis Biomedicine." In Perspectives in Translational Research in Life Sciences and Biomedicine, 265–70. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-0989-1_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mahapatra, Debarshi Kar, and Sanjay Kumar Bharti. "Recent Advances in Bioorganism-Mediated Green Synthesis of Silver Nanoparticles: A Way Ahead for Nanomedicine." In Research Methods and Applications in Chemical and Biological Engineering, 275–89. Series statement: AAP research notes on chemical engineering: Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429424137-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nanomedicine – Research"

1

RAKOVICH, T., A. PRINA-MELLO, A. RAKOVICH, S. J. BYRNE, A. ATZBERGER, J. E. MCCARTHY, Y. K. GUN'KO, and Y. VOLKOV. "APPLICATION OF NANOMATERIALS IN NANOMEDICINE RESEARCH." In Proceedings of International Conference Nanomeeting – 2011. WORLD SCIENTIFIC, 2011. http://dx.doi.org/10.1142/9789814343909_0103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moussa, Heba Adel Mohamed Lotfy, Gawaher Saleh Abbas Mahgoub, Mashael Ali H. I. Al-Badr, and Huseyin Cagatay Yalcin. "Investigating the Cardiac Effects of Sildenafil loaded Nanoparticles on Heart Failure using the Zebrafish Embryo Model." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0217.

Full text
Abstract:
Background: Cardiovascular diseases (CVDs) are the first cause of death worldwide. Vasolidator agents are used to relax cardiac muscle, but their extremely short half-lifes limit their effectiveness. Sildenafil is such an agent used to relax the blood vessels muscles and increase the blood flow. The conventional drug can lead to serious problems in patients duo to the systematic drug delivery. Use of Nanomedicine potentially can enhance delivery of this agent while reducing the systematic effect of the drug. Aim: The purpose of the research is to examine the effectiveness sildenafil loaded nanoparticles in rescuing heart failure using zebrafish embryo model. Methods: There will be five experimental groups. The zebrafish will be treated with Aristolochic Acid (AA) at 24 hour per fertilization (hpf) to create the heart injury group. The treatment groups will be heart injury followed by a dose of either Sildenafil or Sildenafil loaded nanoparticles at 36 hpf. Two control groups will be the negative control (exposed to egg water) and vehicle control (exposed to the Dimethylsulfoxide (DMSO)).To evaluate the drug effects on embryo, toxicity assessment (Survival rate, tail flicking and hatching rate), cardiotoxicity assessment and gene expression of heart injury marker via RT-PCR will be conducted. Results: Preliminary findings demonstrate, loading Sildenafil to nanoparticles enhances its effectiveness dramatically. The experiments are ongoing to confirm the results. Conclusion: Nanomedicine is a powerful approach to enhance cardiovascular therapy. Vasodilator drugs in particular will benefit from this improvement as demonstrated with our findings
APA, Harvard, Vancouver, ISO, and other styles
3

Krishnamoorthy, S. "Nanoscale platform for control, interrogation and optimization of molecular sensing interfaces, toward application to nanomedicine." In 2016 Progress in Electromagnetic Research Symposium (PIERS). IEEE, 2016. http://dx.doi.org/10.1109/piers.2016.7735479.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Preface: International Conference on Bioinformatics and Nanomedicine from Natural Resources for Biomedical Research." In INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND NANO-MEDICINE FROM NATURAL RESOURCES FOR BIOMEDICAL RESEARCH: 3rd Annual Scientific Meeting for Biomedical Sciences. AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5109975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Poojari, Radhika, Mithila Bhujbal, Arti Hole, and Murali Krishna Chilakapati. "Abstract 13: High-Throughput, Non-Invasive Raman Spectroscopy of Anticancer Nanomedicine for Liver Cancer Therapeutic Intervention." In Abstracts: 9th Annual Symposium on Global Cancer Research; Global Cancer Research and Control: Looking Back and Charting a Path Forward; March 10-11, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7755.asgcr21-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ottaviani, Maria Francesca. "Cost Action 17140, 1st STMS Virtual Conference. Book of abstracts." In Cost Action 17140, 1st STMS Virtual Conference. COST Action CA17140, 2022. http://dx.doi.org/10.18778/costaction.

Full text
Abstract:
MARCH 16, 2022; This Book of Abstract is based upon Online Conference of COST Action 17140 „Cancer nanomedicine - from the bench to the bedside“ Nano2Clinic, supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. https://www.nano2clinic.eu/1st-STSM-online-conference
APA, Harvard, Vancouver, ISO, and other styles
7

Al-Ansari, Dana E., Nura A. Mohamed, Isra Marei, Huseyin Yalcin, and Haissam Abou-Saleh. "Assessment of Metal Organic Framework as Potential Drug Carriers in Cardiovascular Diseases." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0127.

Full text
Abstract:
Background: Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as MIL-89 as potential drug carriers in the cardiovascular system. Aims: To assess the effect of MOFs on the viability and cytotoxicity of human vascular cells and the cellular uptake in vitro, and the organ-system toxicity of MOF in vivo using the Zebrafish model. Methods: Human pulmonary endothelial cells (HPAECs) and pulmonary smooth muscle cells (HPASMCs) were treated with variable concentrations of MOFs. The viability, cytotoxicity and anti-inflammatory effects were measured using AlamarBlue, LDH assay and ELISA. The cellular uptake of MOFs were assessed using light, confocal, and transmission electron microscopes and EDS analysis. Moreover, Zebrafish embryos were cultured and treated with MOFs-nanoparticles at 0 hours post fertilization (hpf) followed by different organ-specific assays at 24, 48, and 72 hpf. Results: Although MOFs affect the viability at high concentrations, it does not cause any significant cytotoxicity on HPAECs and HPASMCs. Interestingly, MOFs were shown to have an anti-inflammatory effect. Microscopic images showed an increased (concentration-dependent) cellular uptake of MOFs and transfer to daughter cells in both cell types. Moreover, the in vivo study showed that high concentrations of MOFs delay zebrafish embryos hatching and cause heart deformation, which is currently investigated using cardiotoxicity markers. Conclusion: MOFs is a promising nanoparticle prototypes for drug delivery in the cardiovascular system with high cellular uptake and anti-inflammatory effects. Further investigations of MOFs, including diseased models and drug- loaded formulation is required.
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, Warren C. W. "Elucidating the Interactions of Nanomaterials With Biological Systems." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13377.

Full text
Abstract:
Nanotechnology is a rapidly growing research fields with many applications in biology and medicine. At a heart of nanotechnology research is engineered nanostructures, which possess distinct optical, electronic, and magnetic properties based on their size, shape, and chemical composition. Researchers can now design their surface chemistry with small bi-functional organic molecules or amphiphillic polymers so that they are biocompatible and can be coated with bio-recognition molecules such as antibodies, aptamers, and peptides. Nanoparticles are used as a platform for drug delivery, as a physical trigger for controlling drug release, as a contrast agent for quantifying biological molecules. Thus, the applications of engineered nanostructures are diverse. In this presentation, an overview of the field of nanomedicine is described with an emphasis on results obtained from studying the in vivo interactions of nanostructures as it pertains to their applications in cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Taylor, Robert, Sylvain Coulombe, Todd Otanicar, Patrick Phelan, Andrey Gunawan, Wei Lv, Gary Rosengarten, Ravi Prasher, and Himanshu Tyagi. "Critical Review of the Novel Applications and Uses of Nanofluids." In ASME 2012 Third International Conference on Micro/Nanoscale Heat and Mass Transfer. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/mnhmt2012-75189.

Full text
Abstract:
Nanofluids — one simple product of the emerging world nanotechnology — where nanoparticles (nominally 1–100 nm in size) are mixed with conventional base fluids (water, oils, glycols, etc.). Nanofluids have seen enormous growth in popularity since they were proposed by Choi in 1995 [1]. In the year 2010 alone there were nearly 500 research articles where the term nanofluid was used in the title, showing rapid growth from 2000 (12) and 2005 (78). Much of the first decade of nanofluid research was focused on measuring and modeling fundamental thermophysical properties of nanofluids (thermal conductivity, density, viscosity, convection coefficients). Recent research, however, has started to highlight how nanofluids might perform in a wide variety of other applications. These applications range from their use in nanomedicine [2] to their use as solar energy harvesting media [3]. By analyzing the available body of research to date, this article presents trends of where nanofluid research is headed and suggests which applications may benefit the most from employing nanofluids. Overall, this review summarizes the novel applications and uses of nanofluids while setting the stage for future nanofluid use in industry.
APA, Harvard, Vancouver, ISO, and other styles
10

Benammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph, and Katerina Gorachinova. "Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.

Full text
Abstract:
Introduction: Recently, after a decade of confusing results, several studies pointed out that overexpression of GLUT1 (glucose transporter 1) is a biomarker of worse prognosis in NSCLC. Nonetheless, the presence of transferrin (Tf receptor), which is overexpressed in most cancer tissues and most lung cancers as well, in NSCLC is also an indicator of very poor prognosis. Therefore, these ligands can be used for active targeting of lung cancer cells and improved efficacy of internalization of cancer therapy using nanomedicines. Objectives: Having the background, the main goal of the project was the assessment of the influence of the glucose and transferrin ligands on the efficacy of internalization of the designed (i) glucose decorated PLGA (poly lactic-coglycolic acid) nanoparticles (Glu-PLGA NPs) and (ii) transferrin decorated PLGA nanoparticles (Tf-PLGA NPs) in comparison to (iii) non-liganded PLGA NPs using a A549 lung cancer cells. Methods: Glu-PLGA NPs, Tf-PLGA NPs and PLGA NP - fluorescently labelled), were designed using a sonication assisted nanoprecipitation method. Further, physicochemical properties characterization (particle size analysis, zeta potential, FTIR analysis, DSC analysis), cytotoxicity evaluation using MTT test, and cell internalization studies of DTAF labelled NPs using fluorimetry in A549 NSCLC cell line were performed. Results: The results pointed to a significantly improved internalization rate of the liganded compared to PLGA NPs. Glu-PLGA NPs showed higher internalization rate compared to Tf-PLGA and PLGA NPs, in the serum-supplemented and serumfree medium even at normal levels of glucose in the cell growth medium. Conclusion: The developed nanocarriers offer unique advantages of enhanced targetability, improved cell internalization and decreased toxicity, which makes them promising solution for current therapeutic limitations.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Nanomedicine – Research"

1

Swaan, Peter. Center for Nanomedicine at the University of Maryland in Baltimore to Support Research into New Nanoconstructs. Office of Scientific and Technical Information (OSTI), October 2014. http://dx.doi.org/10.2172/1160083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gorenstein, David. Alliance for NanoHealth (ANH) Training Program for the development of future generations of interdisciplinary scientists and collaborative research focused upon the advancement of nanomedicine. Office of Scientific and Technical Information (OSTI), December 2013. http://dx.doi.org/10.2172/1132629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nanomedicine – Research' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography